Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Seed­ed by Eu­ro­pean VC firm For­bion in 2021, vec­tor­ized an­ti­body start­up Vec­to­rY has an­oth­er $138 mil­lion to work with in a Se­ries A co-led once again by For­bion’s Growth Op­por­tu­ni­ties Fund, with the com­pa­ny call­ing it one of the largest pri­vate biotech fi­nanc­ings in Eu­rope this year.

Vec­to­rY is first go­ing af­ter amy­otroph­ic lat­er­al scle­ro­sis (ALS), al­so known as Lou Gehrig’s dis­ease, in its mis­sion to tar­get neu­rode­gen­er­a­tive dis­eases. The Se­ries A will go to­ward the clin­i­cal de­vel­op­ment of its lead vec­tor­ized an­ti­body pro­gram, VTx-002, which tar­gets TDP-43, the ma­jor patho­log­i­cal pro­tein in spo­radic ALS, ac­cord­ing to the NIH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER